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OBJECTIVES: To systematically review the impact of antibiotic therapy in the neonatal 
period on changes in the gut microbiota and/or antibiotic resistance development. 
METHODS: Data sources were PubMed, Embase, Medline and the Cochrane Database, 
supplemented by manual searches of reference lists. Randomised controlled trials (RCTs) and 
observational studies were included if they provided data on different categories of antibiotic 
treatment (yes versus no, long versus short duration and/or broad versus narrow spectrum 
regimens) and subsequent changes in the gut microbiota and/or antibiotic resistance 
development. We evaluated risk of bias using the Cochrane Handbook, adapted to include 
observational studies. When appropriate, we used the vote-counting method to perform semi-
quantitative meta-analyses. We applied the Grades of Recommendation, Assessment, 
Development and Evaluation approach to rate the quality of evidence (QoE). 
RESULTS: We included 48 studies; three RCTs and 45 observational studies. Prolonged 
antibiotic treatment was associated with reduced gut microbial diversity in all three studies 
investigating this outcome (very low QoE). Antibiotic treatment was associated with reduced 
colonization rates of protective commensal anaerobic bacteria in four of five studies (very low 
QoE). However, all three categories of antibiotic treatment were associated with an increased 
risk of antibiotic resistance development, in particular multi-drug resistance in Gram-negative 
bacteria, and we graded QoE for these outcomes as moderate. 
CONCLUSIONS: We are moderately confident that antibiotic treatment leads to antibiotic 
resistance development in neonates, and it may also induce potentially disease-promoting gut 
microbiota alterations. Our findings emphasize the need to reduce unnecessary antibiotic 
treatment in neonates.  
 
INTRODUCTION 
Upon birth, infants are suddenly exposed to a wide range of bacteria colonizing 
mucoepithelial surfaces, including the gut.1 The subsequent development of the infant gut 
microbiota is dynamic, non-resilient and shaped by factors like mode of delivery, feeding, diet 
and environment.2-4 A healthy gut microbiota has a crucial role in the development of the 
immune systems, digestive functions and protection against infections.4-6 The commensal 
aerobic and anaerobic bacteria are also essential for colonization resistance; the ability to 
prevent invasion and persistent carriage of pathogenic and antibiotic resistant bacteria.7 
 Antibiotics are the most commonly prescribed medications in the neonatal unit.8 
However, antibiotic overuse in early life disrupts the actively developing gut microbiota 
causing “bacterial dysbiosis”, which is associated with an increased risk of early adverse 
outcome such as necrotizing enterocolitis and fungal infections.9 Early antibiotic exposure has 
also been associated with allergic diseases, obesity, diabetes and inflammatory bowel disease 
later in life.10-14 Overuse of antibiotics, particularly broad-spectrum antibiotics, applies a 
selection pressure which favours antibiotic resistant bacteria and decreases colonization 
resistance.7, 15 The currently observed increase in resistance to aminoglycosides and 
ampicillin among Gram-negative bacteria have begun to threaten this traditional combination 
as empiric treatment for neonatal sepsis.16, 17 Moreover, worldwide the emergence of ESBL-
producing Enterobacteriaceae presents major challenges in managing neonatal sepsis.18 
Globally, an estimated 200 000 neonatal deaths are attributed to resistant organisms each 
year.19 However, the relative impact of different types of antibiotic exposure on the actively 
developing gut microbiota composition and antibiotic resistance development is not fully 
understood.  
 The purpose of the current systematic review is to identify, critically appraise, and 
synthesize evidence from studies reporting different categories of antibiotic therapy in 
neonates and their impact on the gut microbiota and/or antibiotic resistance development. We 
 
included both observational studies and randomised clinical trials (RCTs) in line with 
suggestions from the Cochrane group stating that systematic reviews of adverse effects will 
usually need to include non-randomised studies in addition to RCTs. 
 
METHODS 
This review was reported according to the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses following a registered protocol and according to the recommendations 
given by the Cochrane Handbook for Systematic Reviews and Interventions.20-22 We recently 
published a systematic review on early clinical adverse effects of neonatal antibiotic treatment 
from the same research protocol.9 For this review, our primary research question was "Are 
different categories of antibiotic treatment in neonates associated with different changes in gut 
microbiota composition and/or differences in antibiotic resistance development?" 
 
Search Strategy 
We developed our search strategy in consultation with an epidemiologist, a librarian, a 
paediatric pharmacologist and a neonatologist. We searched PubMed, Embase, Medline and 
the Cochrane Database using MeSH-Terms and free text searches with no time restrictions 
(last search 22nd of December 2016). The first search was conducted with MeSH terms in 
PubMed, Medline and the Cochrane Database by combining "Infant, Newborn" and "Anti-
Bacterial Agents" with one of two outcome terms: "Drug Resistance, Bacterial" or 
"Microbiota". The Embase database uses its own key words, and we combined "Newborn" 
and "Antibiotic Agent" with either "Antibiotic Resistance" or "Microbiome". The second 
search was conducted using free text in PubMed, Medline and Embase combining the 
keywords: "Infant, low Birth Weight" or "Infant, Postmature" or "Infant, Premature" or 
"Infant, Newborn" with "Anti-Bacterial Agents" or "Antibiotics" and one of the following: 
"Antibiotic Resistance" or "Antibacterial Drug Resistance" or "Microbiota" or "Microbiome" 
 
or "Microbiomes" or "Gut flora". We examined reference lists of included studies and 
relevant reviews to identify additional eligible studies. We then combined all citations and 
excluded duplicates or triplicates. We did not contact authors for supplementary information 
and we did not perform searches in the grey literature. 
 
Study Selection and Eligibility Criteria 
A study was eligible for review if it reported different categories of intravenous antibiotic 
treatment in the neonatal period and evaluated their impact on changes in the gut microbiota 
and/or antibiotic resistance development. If infants were born prematurely we defined the 
neonatal period up to 44 weeks postmenstrual age. We compared three different categories of 
antibiotic therapy: (1) Antibiotic treatment yes versus no, (2) antibiotic treatment long versus 
short and (3) antibiotic treatment broad versus narrow spectrum. For category (2), we 
suggested in advance that “prolonged” antibiotic exposure was always ≥ 3 days or the longest 
regimen among two antibiotic regimens compared. For category (3), we always defined 
regimens including third-generation cephalosporins or carbapenems as broad-spectrum 
regimens when compared to regimens containing aminoglycosides for coverage against 
Gram-negative bacteria. This definition was based on previous reports indicating that empiric 
therapy containing a third-generation cephalosporin for Gram-negative coverage induces 
significantly more resistance than a regimen containing an aminoglycoside.15 If two similar 
regimens were compared, the regimen with the broadest spectrum was labelled broad-
spectrum. Both RCTs and observational studies such as cohorts, case-control studies, and 
cross-sectional studies were eligible for inclusion. We included case-control studies reporting 
on the prespecified outcomes if data on antibiotic therapy prior to the outcomes were 
presented as extractable data in cases and controls. We excluded case reports and case series, 
studies with a non-neonatal or non-human population, studies that were written in other 
 
languages than English and studies that investigated antenatal antibiotics, oral antibiotics 
and/or low-dose intravenous vancomycin prophylaxis.  
Screening, Data Extraction, and Management 
Two reviewers (JWF and EE) independently screened search results and assessed each 
potentially eligible study per our predetermined inclusion and exclusion criteria. We only 
excluded studies that we agreed were irrelevant according to our predefined criteria. A third 
researcher (CK) had the decisive vote in case of disagreement. We extracted the following 
information from included studies; author, year, country, study design, study population, 
including gestational age (GA) and birth weight (BW), comparison of outcomes between 
groups with different categories of antibiotic treatment and, if available, risk estimates with 
95% CI for the specific outcome.  
 Gut microbiota analyses were based on faecal samples using both standard culture-
based methods and culture-independent methods relying on DNA amplification and 
sequencing.23 After reviewing the articles presenting data on gut microbiota we decided to 
present data from these studies in three main categories; microbial load, microbial diversity 
and microbial composition, clearly acknowledging some overlap between these categories. 
We defined microbial load as the total number of bacteria in a sample, microbial diversity as 
the number of different bacterial genus or species in a sample and microbial composition as 
the taxonomical composition in a sample. Antibiotic resistance development was based on 
detection of antibiotic susceptibility patterns in bacteria isolated from blood, urine, 
cerebrospinal fluid, faeces, tracheal aspirates and/or the skin surface. We defined MDR 
bacteria as bacteria resistant to ≥ 2 unrelated classes of antibiotics or broad-spectrum 
antibiotics.24-28 Included in this category were ESBL-producing Gram-negative bacteria, 
carbapenem-resistant Acinetobacter baumannii (CRAB) and Gram-negative bacteria resistant 
to third-generation cephalosporins. Antibiotic resistant bacteria that did not meet any of these 
criteria were defined as “other antibiotic resistant bacteria”. 
 
We applied a simple vote-counting method to investigate whether the different 
categories of antibiotic therapy had any effect on the outcomes of interest.22 Studies were 
classified based on whether they showed a reduction in the outcome measure, no effect or an 
increase in the outcome measure following antibiotic treatment. When appropriate, outcomes 
were presented in vote-count figures. 
 
Assessment of Methodological Quality 
Methodological quality was assessed by using the Cochrane Handbook of Systematic 
Reviews of Interventions and recently published suggestions on how to assess risk of bias and 
confounding in observational studies.22, 29 Five domains related to risk of bias were assessed 
for each study included: Selection, Performance, Detection, Reporting and Confounding. 
Risks of bias were judged as low, high or unclear for each domain. The risk of reporting bias 
was considered unclear in studies that did not have a previously published protocol. The risk 
of detection bias was considered high in studies that examined gut microbiota with culture-
based methods, unclear in studies that applied 16S rRNA sequencing techniques and low in 
studies that applied shotgun metagenome sequencing techniques. Two reviewers (JWF and 
EE) assessed the risks of bias for of each study. Disagreements in the categorization process 
were resolved after discussion between JWF, EE and CK.  
  We applied the Grades of Recommendation, Assessment, Development and 
Evaluation Working Group (GRADE) approach to rate the quality of evidence (QoE) for each 
relevant outcome category.30 This approach specifies four levels of quality from high to very 
low, which define the degree to which its' estimates of effects or associations can be trusted.22, 
30 RCTs started as high QoE and observational studies started as low QoE.30 Several factors 




Overview of Included Studies 
From 3380 identified studies, we reviewed 137 potentially eligible full-text articles. Forty-
eight studies met our inclusion criteria: three RCTs published between 2000 and 201315, 31, 32 
and 45 observational studies published between 1974 and 2016 (Figure 1).24-28, 33-73 Two 
articles presented data from the same study population and were defined as one study.34, 35 
Antibiotic treatment was the randomized intervention in two out of three included RCTs.15, 31, 
32 Among the 45 observational studies, there were 22 prospective cohort studies, 12 case-
control studies, seven before-after studies and four retrospective cohort studies. There were 
large variations regarding the categories of antibiotic therapy studied. Tables S1-S2 (available 
as Supplementary data at JAC online) display the main characteristics and primary outcomes 
of interest from the 48 included studies. 
 
Risk of Bias and Quality of Evidence (QoE) 
Figure S1a-b (available as Supplementary data at JAC online) display risk of bias assessments 
for each included study. Outcomes adjusted for differences in populations were reported in 
16/45 (36%) observational studies.25, 26, 28, 39, 44, 46, 50, 52, 55, 57, 63, 64, 67, 69-71 Five of these studies 
used stratification or multivariate analysis to adjust for antenatal antibiotic treatment as a 
potentially confounding variable. None of the RCTs were included in public registries.  
 We graded the QoE as very low for the outcomes microbial load and microbial 
diversity in relation to the three different categories of antibiotic treatment due to inclusion of 
observational studies with serious risk of bias and inconsistent results. We graded the QoE as 
very low for the outcomes relating to microbial composition after antibiotic treatment (Figure 
2a-d). We graded the QoE as moderate for the outcomes relating to antibiotic resistance 
development due to inclusion of observational studies that either had large effect sizes (yes 
 
versus no and broad versus narrow) or a dose-response effect (long versus narrow) after 
antibiotic treatment (Figure 3a-c).  
 
Gut Microbiota Composition 
Nineteen studies reported on antibiotic exposure and impact on the gut microbiota 
composition (Table SI). There were two RCTs31, 32 and 17 observational studies.33-49, 73 Three 
studies reported outcome data from both antibiotic treatment yes versus no and broad versus 
narrow spectrum,34, 37, 47 and one study reported outcome after antibiotic treatment yes versus 
no and long versus short.42 The remaining 15 studies reported outcome data from one 
category of antibiotic treatment. To examine gut microbiota composition, nine studies used 
16S rRNA gene-sequence analysis,33, 38-40, 42, 44-46, 49 one used fluorescent in situ hybridisation 
techniques,32 one used deep shotgun metagenome sequence analysis48 and eight used standard 
culture-based methods.31, 34-37, 41, 43, 47, 73 The included studies reported primarily taxonomic 
data with different hierarchical details on i) Enterobaceriaceae, ii) obligate commensals 
anaerobic bacteria (e.g. bacteroides, lactobacilli and bifidobacteria etc.), iii) clostridia and/or 
iv) Gram-positive cocci. 
 
Microbial Load 
Three studies (296 neonates) compared the impact of antibiotic treatment (yes versus no) on 
microbial loads.32, 34, 40 One study (165 neonates) found increased microbial loads,34 one RCT 
(113 preterm neonates) found decreased microbial loads,32 while one study (18 term neonates) 
found no significant differences in microbial loads following antibiotic treatment.40 A small 
study of extremely low birth-weight neonates found an inverse correlation between the 




Four studies (159 neonates) compared microbial diversity after antibiotic treatment (yes 
versus no).40, 42, 44, 49 Two studies (112 preterm neonates) reported decreased diversity among 
antibiotic treated neonates42, 49 and two studies (47 neonates) reported no significant 
differences.40, 44 Three studies (224 preterm neonates) examined the impact of antibiotic 
therapy duration (long versus short) on microbial diversity, and all three found decreased 
diversity following prolonged therapy.41, 44, 48 
 
Microbial Composition 
Figure 2 displays the results of studies reporting the impact of antibiotic treatment (yes versus 
no) on microbial composition. Nine studies focused on Enterobacteriaceae; four reported an 
increase and five studies reported unchanged composition after antibiotic treatment, mainly 
ampicillin plus an aminoglycoside (Figure 2a).33, 34, 36, 37, 40, 42, 43, 46, 47 Five studies focused on 
different commensal obligate anaerobes showing a clear trend towards reduced colonization 
rates following treatment (Figure 2b).35, 36, 38, 40, 43 In the five studies focusing on clostridia, 
there were equivocal results (Figure 2c).36, 39, 40, 45, 46 Finally, four studies focused on Gram-
positive cocci, and these studies showed either unchanged or higher colonization rates after 
antibiotic treatment (Figure 2d).33, 36, 37, 40    
 Two studies (n=983) reported Enterobacteriaceae colonization rates after treatment 
with broad versus narrow spectrum antibiotics.37, 47 Both studies found lower colonization 
rates following third-generation cephalosporin treatment. One study of preterm infants (n=76) 
reported lower colonization rates of clostridia in those who received ≥ 10 days of antibiotic 
therapy compared with shorter duration.39 Another study with preterm infants (n=74) reported 
higher colonization rates of staphylococci in those who received ≥ 5 days of antibiotic 
treatment compared with shorter duration therapy.42 Finally, two studies (n=104) compared 
 
the impact of antibiotic therapy (broad versus narrow) on abundance and/or colonization rates 
with staphylococci, but neither found any significant differences.37, 42  
 
Antibiotic Resistance Development 
Thirty-one studies, two RCTs15, 31 and 29 observational studies,24-28, 37, 50-72 evaluated the risk 
of antibiotic resistance development after antibiotic exposure (Table S2). Five studies 
reported outcome after antibiotic treatment yes versus no and broad versus narrow 
spectrum.27, 37, 53, 55, 67 Two studies reported outcome after antibiotic treatment long versus 
short duration and broad versus narrow spectrum.26, 64 Two studies reported outcome after 
antibiotic treatment yes versus no and long versus short duration.25, 57 The remaining 23 
studies assessed only one category of antibiotic therapy.  
 Nine studies reported on both infections and colonization with antibiotic-resistant 
bacteria,24, 51, 57, 58, 60, 62, 65, 67, 68 while 15 studies only reported on colonization,15, 25-27, 31, 37, 53-56, 
59, 61, 66, 69, 72 and seven studies only reported on infections.28, 50, 52, 63, 64, 70, 71 MDR bacteria 
were varyingly defined as bacteria resistant to both third-generation cephalosporins and 
aminoglycosides55, 58 or bacteria resistant to ≥ 2 or ≥ 3 unrelated classes of antibiotics.24-28 
Thirty of 31 studies focused solely on antibiotic resistance development in Gram-negative 
bacteria. Among these, 20 studies focused on MDR Gram-negative bacteria. 
 
MDR Gram-negative bacteria 
Figure 3 displays the results of the 20 studies reporting the impact of antibiotic exposure on 
rates of infection and/or colonization with MDR Gram-negative bacteria. Nine studies 
reported data after antibiotic treatment yes versus no, and the majority reported increased 
rates of MDR Gram-negative bacteria following treatment (Figure 3a).25, 27, 55, 57, 59, 63, 67, 69, 70 
Five studies reported data after long versus shorter duration of treatment, and the majority 
found significantly more MDR Gram-negative bacteria after prolonged treatment (Figure 
 
3b).25, 26, 56, 57, 64 Thirteen studies reported data after treatment with broad spectrum versus 
narrow spectrum antibiotics, and the overwhelming majority reported higher rates of MDR 
Gram-negative bacteria following treatment with broad spectrum antibiotics (Figure 3c).15, 24, 
26-28, 50, 51, 55, 58, 64, 65, 67, 71 
 
Other antibiotic resistant bacteria 
Four studies (n=1825) compared the impact of antibiotic treatment (yes versus no) on 
antibiotic resistant bacteria that were not MDR according to our definition.37, 52, 53, 66 One 
study (n=584) found a higher rate of prior antibiotic treatment in neonates colonized with 
antibiotic resistant Escherichia coli and/or Klebsiella pneumonia.66 One study (n=953) found 
an increased incidence of TEM-1 genes in E. coli strains in neonates following antibiotic 
therapy.53 Two studies (n=288) found no statistically significant associations between 
antibiotic treatment (yes versus no) and subsequent antibiotic resistance development.37, 52 
Two studies compared the impact of antibiotic therapy duration;61, 72 one of them (n=1180) 
found significantly longer prior antibiotic treatment among neonates colonized with antibiotic 
resistant Gram-negative bacteria,72 while the other (unknown number of neonates) found no 
correlation between the duration of treatment and gentamicin-resistant Gram-negative 
bacteria.61 
 Eight studies (n=3029) compared the impact of broad- versus narrow-spectrum 
antibiotic treatment.31, 37, 53, 54, 60, 62, 68, 72 One RCT (n=276) found higher colonization rates 
with ampicillin-resistant Acinetobacter baumannii following treatment with penicillin and 
gentamicin compared with ampicillin and gentamicin.31 One study (n=440) found a higher 
rate of both ampicillin and cefuroxime resistance in Gram-negative bacteria following 
treatment with ampicillin compared with cefuroxime.62 One study (n=118) found a higher rate 
of gentamicin resistance among Gram-negative bacteria following treatment with gentamicin 
compared with amikacin.68 The remaining five studies (n=2195) did not formally test for 
 
statistically significant differences when comparing broad versus narrow spectrum 
regimens,37, 53, 54, 60, 72 but 3/5 studies (n=1258) reported increased rates of antibiotic resistance 
following broad-spectrum therapy.54, 60, 72 
 
DISCUSSION 
Key Findings  
To our knowledge, this is the first systematic review to examine antibiotic therapy in neonates 
and its impact on gut microbiota and/or antibiotic resistance development. The primary 
findings were the lack of RCTs and large high-quality observational studies and the 
heterogeneity regarding methodology and outcomes among the included studies. Despite this, 
there were several salient features in this review.  
 First, prolonged antibiotic therapy was associated with reduced gut microbial 
diversity.41, 44, 48 Decreased gut microbial diversity has been associated with early adverse 
outcomes such as NEC, and may have potential long lasting consequences through increased 
likelihood of obesity and inflammatory diseases.10, 49, 74-77 Combined, these findings imply 
that prolonged exposure to antibiotic treatment in the neonatal period may increase the 
likelihood of disease, either in the neonatal period or later in life. However, QoE for this 
outcome was graded as very low. It is possible that neonatal antibiotic therapy, regardless of 
treatment length, leads to decreased microbial diversity, but the included studies in this 
category were small and two out of four studies did not detect a significant difference.40, 42, 44, 
49 Second, four out of nine studies reported increased abundance and/or colonization 
rates of Enterobacteriaceae following neonatal antibiotic treatment, while none of the studies 
reported reduced abundance.33, 34, 36, 37, 40, 42, 43, 46, 47 In the majority of these studies, the 
empiric regimens consisted of ampicillin and gentamicin. We speculate that intravenous 
ampicillin also has an impact on Gram-positive gut bacteria despite being mainly secreted 
through the kidneys,78 while intravenous gentamicin mainly covering Gram-negative bacteria 
 
in the blood stream,79 has a very low penetration into the gut. Combined, this may give undue 
benefits to the Gram-negative Enterobacteriaceae. In contrast, third-generation cephalosporin 
therapy may lead to a relatively lower abundance of Enterobacteriaceae as both Gram-
negative and Gram-positive bacteria are within their spectrum of activity.79 However, QoE for 
this outcome was again graded as very low, and even though overgrowth of 
Enterobacteriaceae in the human gut has previously been associated with NEC, inflammatory 
bowel disease and chronic fatigue syndrome there is no strong evidence of any causal 
relationship.74, 76, 80-82 
 Third, antibiotic treatment in the neonatal period was strongly associated with reduced 
abundance of protective commensal anaerobic bacteria such as bifidobacteria, lactobacilli 
and/or bacteriodes.35, 40, 43 These bacteria provide colonization resistance against antibiotic 
resistant bacteria and potentially pathogenic bacteria such as Enterobacteriaceae and 
Clostridium difficile.7 Moreover, it is well known that bifidobacteria may reduce expression 
of inflammatory response genes and stimulates genes promoting the integrity of the mucosal 
barrier. The QoE for this outcome was graded as very low, but our results are in line with 
findings in adult populations showing decreased diversity, reduced colonization rates of 
obligate anaerobes and increased colonization rates of Proteobacteria following antibiotic 
exposure.83-85 Furthermore, our findings are biologically plausible as reduced numbers of 
bifidobacteria and lactobacilli seem to increase the risk of necrotising enterocolitis in preterm 
infants with an exaggerated inflammatory response.82, 86-90 In adults some studies have found 
larger changes in the gut microbiota than oral microbiota following antibiotic treatment, with 
larger resilience in the oral communities. 84,85 However, we believe that the gut microbiota is 
of highest clinical relevance, both as the largest reservoir for antibiotic resistant bacteria and   
because the gut is characterised as the motor of multiple organ dysfunction syndrome. 
 Fourth, all three categories of neonatal antibiotic treatment investigated in this review 
were clearly associated with an increased risk of antibiotic resistance development, in 
 
particular ESBL-producing Gram-negative bacteria and other MDR bacteria. These findings 
were based on moderate QoE. Antibiotic resistance genes exist even in the absence of 
antimicrobial drugs.91, 92 Moreover, overuse of antibiotics may lead to increased antibiotic 
resistance through several mechanisms.91, 93 Antibiotics apply a direct selection pressure that 
gives significant advantages to bacteria expressing resistance genes.94 Antibiotic treatment 
also contributes to changes in the human gut-associated resistome, which comprise numerous 
functional antibiotic resistance genes in the gut microbiota.95 Gibson and colleagues recently 
found that only a fraction of antibiotic resistance genes that are enriched after a specific 
antibiotic therapy are unique to the particular antibiotic given.96 Finally, antibiotic treatment 
appears to reduce colonization resistance against antibiotic resistant bacteria through the 
collateral destruction of obligate anaerobic bacteria.7, 97 An increase in the gut resistome and a 
decrease in colonization resistance could theoretically increase horizontal transfer of 
antibiotic resistance genes from commensals to potential pathogens.98 Although in vivo 
horizontal transfer between commensals and pathogens in the gut microbiota remains to be 
shown, there is evidence of exchange of antibiotic resistant genes between environmental 
bacteria and human pathogens.99  
 
Strengths and Limitations 
The primary strength of this study is our rigorous and sensitive search strategy based on a 
previously registered search protocol. Additionally, the adverse impact of the developing 
infant gut microbiota is of great clinical and scientific interest. The main limitations were the 
lack of RCTs and the diverse studied outcomes which made meta-analysis impossible to 
perform. Instead, we applied a semi-quantitative vote-counting method to assess the effect of 
neonatal antibiotic treatment on relevant outcomes. This method has limitation as it usually 
fails to take account of the population sizes and methodological quality of pooled studies. 
Still, vote counting may be an effective method to assess ranking of outcomes.100 Moreover, 
 
we attempted to improve the method by presenting the differential weight of each study with 
squares corresponding to sample size.  
 The majority of studies included were small and there was a large heterogeneity in 
study designs, outcomes, categories of antibiotic treatment and methodological quality. 
Observational studies are prone to biases and confounding, and only a third of the included 
studies attempted to adjust for confounding through multivariable regression analysis. 
Evidence from observational studies is usually considered to be of low quality. However, well 
designed observational studies have been shown to provide similar results to RCTs and they 
can therefore be useful for detecting rare adverse outcomes by allowing larger sample sizes 
and longer lengths of follow up than RCTs for lower costs.101 We used the GRADE approach 
to assess QoE. Overall, we graded QoE as very low for all outcomes presented in the gut 
microbiota category. In contrast, we considered the QoE as moderate in the antibiotic 
resistance category due to large effect sizes and a dose-response effect. Based on current 
evidence we are therefore moderately confident that all types of antibiotic treatment lead to 
increased rates of antibiotic resistance. 
 All included studies published prior to 2007 used culture-based techniques to examine 
the gut microbiota composition. It has been estimated that < 20% of environmental bacteria 
can be grown in defined growth media. This increases the risk of detection bias in older 
studies.102 Sequencing-based techniques also have limitations. Studies relying on 16S rRNA 
analysis allow only a coarse sorting of bacteria mainly at phylae level. Deep shotgun 
metagenom sequencing allows for finer distinction at genus or species level, but it is of 
crucial importance to standardize sampling and temperature control during the pipeline up to 
DNA extraction in order to obtain valid results.103 Moreover bioinformatic presentations are 
often challenging to understand and interpret.  
 We also acknowledge that our definition of broad-spectrum and narrow-spectrum 
antibiotics is somewhat arbitrary as most of the narrow-spectrum regimens covered both 
 
Gram-negative and Gram-positive bacteria. However, our study confirms previous findings 
clearly suggesting that antibiotic regimens containing third-generation cephalosporins or 
carbapenems are more frequently associated with antibiotic resistance development than 
regimens with aminoglycosides for Gram-negative coverage.15, 24, 26, 28, 50, 55, 64, 65, 67, 71 Finally, 
we decided to exclude studies that only examined antenatal antibiotic treatment, despite the 
frequent use of intrapartum antibiotic prophylaxis for prevention of neonatal infections and its 
reported effects on the infant gut microbiota and carriage of antibiotic resistance genes.104 The 
focus of this review was on neonatal antibiotic treatment given for suspected neonatal 
infection, and the isolated effects of antenatal antibiotics, given to infants that did not receive 
antibiotics after birth, were beyond the scope of this study. 
 
Implications and Conclusion 
This systematic review highlights the profound impact on the gut microbiota and antibiotic 
resistance development exerted by antibiotic treatment in neonates. Antibiotic exposure in the 
neonatal period appears to induce varying potentially disease-promoting alterations in the gut 
microbiota, but quality of evidence was very low for outcomes investigated in this review. 
However, we are moderately confident, based on data from this review, that antibiotic 
treatment leads to antibiotic resistance development, in particular in Gram-negative bacteria. 
This clearly threatens current empiric antibiotic regimens and is a finding of great concern.  
 In conclusion, the findings from this systematic review, along with the findings from 
our recent systematic review on early adverse outcome of neonatal antibiotic therapy9, 
strongly emphasize the need to reduce unnecessary antibiotic treatment in neonates. Important 
steps to reduce the burden of neonatal antibiotic therapy include improving preventive 
measures such as hand hygiene, stopping antibiotic therapy after 36-48 hours if only vaguely 
suspected infection and no growth in the blood culture and restricting the empiric use of 
broad-spectrum antibiotic treatment.105, 106 
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Figure 2. Vote count on gut microbial composition after antibiotic exposure – compared to no antibiotic exposure.  
The sizes of squares are proportional to study populations. * symbolizes a lack of testing for statistical significance. 
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c) Clostridium species (5 studies; 248 neonates) 
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Figure 3. Vote count on infection and/or colonization with MDR Gram-negative bacteria following antibiotic exposure. The sizes of 
squares are proportional to study populations. † symbolizes multivariate regression analysis. NDA; no data available. 
 
a) Antibiotic exposure  - compared to no antibiotic exposure  (9 studies; 2509 neonates) 
Study 
Infection and/or colonization rates 
Risk estimates Specific outcomes 
Colonization 
or infection Lower Unchanged Higher 
Calil, 2001   
 
OR 2.5, 95% CI 1.08-5.77† MDR E. cloacae Colonization 
Crivaro, 2007   
 
Not available  
ESBL producing S. marcescens & 
K. pneumoniae 
Colonization 
Duman, 2005   
 
RR 14.05; 95% CI 1.19-164.62 ESBL producing Enterobacteriaceae Colonization 
Giuffre, 2016   
 




ESBL producing Gram-negative 
bacteria 
Colonization 
Kumar, 2014   
 
OR 26.04, 95% CI 3.51-35.45† Carbapenem-resistant A. baumannii Infection 
Millar, 2008  
 
 Not available  MDR Enterobacteriaceae Colonization 
Pessoa-Silva, 2003  
 
 OR 3.23, 95% CI 0.99-10.49 ESBL-producing K. pneumoniae Infection 
Rettedal, 2013   
 
OR 5.5; 95% CI 5.6-15.3† ESBL-producing K. pneumoniae Colonization 
Sehgal, 2007   
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Figure S1. Risk of bias graph: review of authors' judgements about each risk of bias item for 1 
each included study and the two outcomes. (a) studies reporting on changes in gut microbiota 2 
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Table S1. Studies reporting previous antibiotic exposures and the effect on gut microbiota: Summary of main characteristics and results 
 
Study Design N GA and BW Empiric regimen Categories of antibiotic exposure and changes in gut microbiota 




40 All GAs EOS: AMP + GEN, LOS: 
VAN + AMK 
Yes vs. no: Composition:  Staphylococcus spp. & Comamonadaceae 
Bennet et al., 1986 
& 1987 (Sweden) 
Prospective 
cohort 
164 All GAs NDA Yes vs. no: Load: ; Composition:  Klebsiella/Enterobacter spp., 
 Anaerobes, Bifidobacterium spp., Lactobacillus spp., Bacteriodes spp. 
Broad vs. narrow: Composition:  Enterococcus spp.,  S. faecalis 




28  GA ≤ 36 weeks EOS: PEN + GEN Yes vs. no: Composition: No difference* 




30 All GAs EOS: AMX + NET ± CTX Yes vs. no: Composition: No difference Broad vs. narrow: Composition: No 
difference* 




52 GA 30 - 35 weeks NDA Yes vs. no: Composition: No significant difference 




76 GA < 36 weeks NDA Yes vs. no: Composition:  C. butyricum Long vs. short: Composition:  
Clostridium spp. 




18 GA ≥ 37 weeks AMP + GEN Yes vs. no: Composition:  Enterobacteriaceae, Gammaproteobacteriae,  
Peptostreptococcaceae,  Enterococcus spp.,  Clostridium spp., 
 Lactobacillus spp.,  Bifidobacterium spp.,  Bacteriodetes 




29 BW < 1000 g EOS: AMP + GEN, LOS: 
VAN + CTX 
Long vs. short: Load: ; Diversity:  




63 All GAs NDA Long vs. short: Composition:  Klebsiella spp.,  Enterobacter spp., and/or 
 Citrobacter spp. 




74 GA ≤ 32 weeks EOS: AMP + GEN Yes vs. no: Diversity: ; Composition:  Enterobacter spp. Long vs. short: 
Composition:  Enterobacter spp.,  Staphylococcus spp. 




42 GA ≤ 33 weeks NDA Broad vs. narrow: Composition:  Lactobacillus spp. 




29 GA ≤ 30 weeks EOS: AMK + (1) PEN or (2) 
AMP or (3) CTX, LOS: VAN 
+ AMK 
Yes vs. no: Diversity: No significant effect Long vs. short: Diversity:  




68 GA < 27 weeks NDA Yes vs. no: Composition:  C. difficile 




58 BW ≤ 1500 g NDA Yes vs. no: Composition:  Gammaproteobacteria (GA ≥ 26 weeks), 
 Clostridium spp. (GA ≤ 28 weeks) 
Parm et al., 2010 
(Estonia) 
RCT 276 All GAs EOS: (1) PEN + GEN or (2) 
AMP + GEN 
Broad vs. narrow: Composition:  S. haemolyticus,  S. hominis, 
 K. pneumonia,  Enterococcus spp.  S. aureus 
3 
 




953 All GAs AMP + GEN Yes vs. no: Composition:  E. coli Broad vs. narrow: Composition: No 
significant difference 
Ward et al., 2016 
(USA) 
Case-control 166 All GAs EOS: AMP + GEN Long vs. short: Diversity:  
Westerbeek et al., 
2013 (Netherlands) 
RCT 113 GA < 32 weeks 
± BW < 1500 g 
NDA Yes vs. no: Load:  
Zhou et al., 2015 
(USA) 
Case-control 38 GA < 32 weeks NDA Yes vs. no: Diversity:  
 
Outcomes: Load; the total number of bacteria in a sample, Diversity; the number of bacterial genus or species in a sample, and Composition; the taxonomical composition in a 
sample. Categories: Yes vs. no compares neonates exposed to antibiotics with non-exposed neonates, Long vs. short compares long and short treatment durations, Broad vs. 
narrow compares broad spectrum antibiotic treatment to narrow spectrum treatment. *; did not test for statistical significance, RCT; randomized controlled trial, GA; 
gestational age, PNA; post-natal age, BW; birth weight, g; gram, EOS; early onset sepsis, AMP; ampicillin, GEN; gentamicin, LOS; late onset sepsis, VAN; vancomycin, 
AMK; amikacin, NDA; no data available, PEN; penicillin, AMX; amoxicillin, NET; netilmicin, CTX; cefotaxime 
4 
 
Table S2. Studies reporting on previous antibiotic exposures and the risk of antibacterial resistance: Summary of main characteristics 
and results 
 
Study Design N Empiric regimen Categories of antibiotic exposure and changes in antibacterial 
resistance 




380 NDA Broad vs. narrow:  ESBL producing K. pneumoniae infection 
Acolet et al., 1994 
(UK) 
Case-control 60 EOS: AMX + CTX, LOS: CTX Broad vs. narrow:  CREC colonization 
Bergin et al., 2015 
(USA) 
Case-control 258 NDA Broad vs. narrow: No significant difference 




30 EOS: AMX + NET ± CTX Yes vs. no: Did not assess significance Broad vs. narrow: Did not assess 
significance 




953 EOS: (1) AMP + GEN or (2) CTX Yes vs. no:  TEM-1 in E. coli Broad vs. narrow: No significant difference 




46 EOS: (1) AMP + GEN or (2) CTX Yes vs. no: E. cloacae:  MIC to ampicillin, cephalotin, cephalexin 




342 EOS: AMX + (1) GEN or (2) CRO, LOS: 
OXA + (1) GEN or (2) CRO 
Yes vs. no:  MDR E. cloacae colonization Broad vs. narrow:  MDR E. 
cloacae colonization 




2502 EOS: AMX + GEN, LOS: OXA + GEN Long vs. short: No significant difference 
Crivaro et al., 2007 
(Italy) 
Case-control 167 AMP + GEN Yes vs. no:  ESBL-producing S. marcescens and K. pneumoniae Long vs. 
short:  ESBL-producing S. marcescens and K. pneumoniae 




995 PEN & GEN Broad vs. narrow:  MDR GNB 




636 (1) AMP + GEN or (2) AMP + AMK Broad vs. narrow:  Gentamicin-resistant, cephalosporin-resistant, and   MDR 
E. cloacae,  Amikacin-resistant P. aerunginosa;  Gentamicin & amikacin-
resistant GNB, MRSE 
De Man et al., 2000 
(Netherlands) 
RCT 436 EOS: (1) PEN + TOB or (2) AMX + CTX, 
LOS: FLU + (1) TOB or (2) CTX 
Broad vs. narrow:  Colonization with cefotaxime-resistant Enterobacter spp. 
& GNB 




118 NDA Yes vs. no:  ESBL-producing Enterobacteriaceae colonization 
Gaynes et al., 1984 
(USA) 
Case-control 32 (1) PEN or (2) AMP + (1) GEN or (2) 
KAN 
Yes vs. no:  Aminoglycoside-resistant E. coli 




1152 SAM + GEN Yes vs. no:  MDR GNB colonization Long vs. short:  MDR & ESBL-
producing GNB colonization 
5 
 




NDA EOS: PEN + (1) NET or (2) GEN, LOS: 
FLU + (1) NET or (2) GEN 
Long vs. short: No significant difference 




440 (1) AMP + GEN or (2) CXM + GEN Broad vs. narrow:  Ampicillin-resistant GNB, cefuroxime-resistant GNB & 
cefuroxime-resistant K. pneumoniae 
Kumar et al., 2014 
(India) 
Case-control 65 NDA Yes vs. no:  CRAB blood stream infections 




250 EOS: AMP + GEN, LOS: VAN + (1) CTX 
or (2) TOB 
Long vs. short:  ESBL-producing Enterobacteriaceae infection Broad vs. 
narrow:  ESBL-producing Enterobacteriaceae infection 
Linkin et al., 2004 
(USA) 
Case-control 10 NDA Yes vs. no:  ESBL-producing Enterobacteriaceae 




210 EOS: SAM + GEN Long vs. short:  MDR GNB colonization Broad vs. narrow:  MDR GNB 
colonization 




124 EOS: PEN + GEN, LOS: (1) TZP + VAN 
or (2) FLU + GEN 
Yes vs. no: No significant difference Broad vs. narrow:  MDR 
Enterobacteriaceae colonization 




584 NDA Yes vs. no:  Antibiotic-resistant E. coli & Klebsiella spp. colonization 
Parm et al., 2010 
(Estonia) 
RCT 276 EOS: (1) PEN + GEN or (2) AMP + GEN Broad vs. narrow:  Ampicillin-resistant Acinetobacter spp. colonization  




379 EOS: AMP + GEN, LOS: Varying 
antibiotics 
Yes vs. no:  ESBL-producing K. pneumoniae colonization 




118 (1) AMP + GEN or (2) AMP + AMK Broad vs. narrow:  Gentamicin-resistant GNB and E. cloacae 
Rettedal et al., 2013 
(Norway) 
Case-control 99 NDA Yes vs. no:  ESBL-producing K. pneumoniae colonization 
Sehgal et al., 2007 
(India) 
Case-control 63 EOS: AMP + GEN, LOS: 
3rd gen. cephalosporin + AMK 
Yes vs. no:  ESBL-producing GNB blood stream infection 
Thatrimontrichai et 
al., 2013 (Thailand) 
Case-control 96 EOS: AMP + GEN, LOS: 3rd gen. 
cephalosporin + AMK 
Broad vs. narrow:  CRAB blood stream infection 
Thatrimontrichai et 
al., 2016 (Thailand) 
Case-control 101 EOS: AMP + GEN, LOS: varying 
antibiotics 
Broad vs. narrow:  odds of CRAB ventilator associated pneumonia 




1180 NDA Long vs. short:  antibiotic resistant GNB colonization 
 
Categories: Yes vs. no; compares neonates exposed to antibiotics with non-exposed neonates, Long vs. short; compares long and short treatment durations, and Broad vs. 
narrow; compares broad spectrum antibiotic treatment to narrow spectrum treatment. RCT; randomized controlled trial, NDA; no data available, EOS; early onset sepsis, 
AMX; amoxicillin, CTX; cefotaxime, LOS; late onset sepsis, NET; netilmicin, AMP; ampicillin, GEN; gentamicin, CRO; ceftriaxone, OXA; oxacillin, TOB; tobramycin, 
FLU; flucloxacillin, KAN; kanamycin, SAM; ampicillin/sulbactam, CXM; cefuroxime, TZP; piperacillin/tazobactam, CREC; cephalosporin-resistant Enterobacter cloacae, 
GNB; Gram-negative bacteria, CRAB; carbapenem-resistant Acinetobacter baumannii 
